GlassScriptPhysician profile
Rachel Beth Vanwettering
NPI 1548965676
$1,985.54
in general payments reported to CMS, 2019-2025
27 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 90% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $328 · 2024: $445 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.55 |
| Education | $154.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $412.77 | 2023-2025 | |
| Janssen Biotech, INC. | $249.24 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $188.16 | 2023-2025 | |
| Incyte Corporation | $178.14 | 2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $173.91 | 2023-2025 | Jardiance, Mounjaro, Ebglyss |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.77 | 2023-2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $63.41 | 2023-2024 | Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $53.35 | 2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.04 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $46.97 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $44.27 | 2023-2024 | |
| Amgen INC. | $42.07 | 2023-2024 | Evenity, Prolia |
| Biofrontera INC. | $39.53 | 2025 | Ameluz |
| Mylan Specialty L.P. | $38.94 | 2024 | Yupelri |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $33.22 | 2024 | Senza |
| Regeneron Healthcare Solutions, INC. | $31.07 | 2025 | Dupixent |
| Astellas Pharma US INC | $29.71 | 2024 | Veozah |
| Ucb, INC. | $27.47 | 2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.87 | 2025 | Cabtreo |
| Genzyme Corporation | $20.72 | 2025 | |
| Lundbeck LLC | $17.84 | 2024 | Rexulti |
| Galderma Laboratories, L.P. | $16.34 | 2025 | Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $16.23 | 2025 | Valchlor |
| Leo Pharma INC. | $14.59 | 2025 | Anzupgo |
| Glaxosmithkline, LLC. | $14.37 | 2023 | Shingrix |
| Organon LLC | $7.55 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Vanwettering listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.